Background : Rosiglitazone is a novel thiazolinedione anti-diabetic drug and metabolized by cytochrome P450 2C8. A number of studies have evaluated the pharmacokinetic profiles of rosiglitazone in different ethnic groups but there is no available data for Korean subjects. Methods : Nine healthy Korean male subjects were treated 8 mg rosiglitazone orally. Plasma rosiglitazone concentrations were measured using high performance liquid chromatography and pharmacokinetic analysis was done using non-compartmental method. Results : Pharmacokinetic variables of rosiglitazone in Koreans healthy subjects are as follows: ${C_{max},;535.6;{pm};123.9 ;ng/mL;}$ elimination half life, ${3.9;{pm};0.3h;;AUC_{0-inf},;2886.2 ;{pm};471.8;ng{cdot}h/mL,}$ oral clearance, $2.8;{pm};0.5 L/h$. The variation of pharmacokinetic variables was less than 20% except $C_{max};and;T_{max}$. Conclusion: This study showed that Korean showed similar pharmacokinetic characteristics to Caucasians.